Dextroamphetamine - Generic Drug Details

What are the generic drug sources for dextroamphetamine and what is the scope of patent protection?

Dextroamphetamine is the generic ingredient in seven branded drugs marketed by Noven Pharms Inc, Impax Labs Inc, Able, Actavis Elizabeth, Nesher Pharms, Pharmobedient, Senores Pharms, Specgx Llc, Strides Pharma, Strides Pharma Intl, Teva, Glaxosmithkline, Prasco, Tris Pharma Inc, Ani Pharms, Aurolife Pharma Llc, Avanthi Inc, Azurity, Barr, Epic Pharma Llc, Halsey, Lannett, Mast Mm, Novel Labs Inc, Nuvo Pharm, Purepac Pharm, Sandoz, Vitarine, Winder Labs Llc, Shire, and Ferndale Labs, and is included in forty-one NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dextroamphetamine has twenty-five patent family members in eleven countries.

There are eighteen drug master file entries for dextroamphetamine. One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for dextroamphetamine

International Patents:	25
US Patents:	3
Tradenames:	7
Applicants:	31
NDAs:	41
Drug Master File Entries:	18
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	17
Clinical Trials:	32
Drug Prices:	Drug price trends for dextroamphetamine
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for dextroamphetamine
What excipients (inactive ingredients) are in dextroamphetamine?	dextroamphetamine excipients list
DailyMed Link:	dextroamphetamine at DailyMed

See drug prices for dextroamphetamine

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for dextroamphetamine

Dosage:

SYSTEM;TRANSDERMAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for dextroamphetamine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eva Szigethy	Phase 4
The Beckwith Institute	Phase 4
Vallon Pharmaceuticals, Inc.	Phase 1

See all dextroamphetamine clinical trials

Generic filers with tentative approvals for DEXTROAMPHETAMINE

Applicant	Application No.	Strength	Dosage Form
		30MG	CAPSULE, EXTENDED RELEASE;ORAL
		25MG	CAPSULE, EXTENDED RELEASE;ORAL
		20MG	CAPSULE, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for dextroamphetamine

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

US Patents and Regulatory Information for dextroamphetamine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	DEXAMPEX	dextroamphetamine sulfate	TABLET;ORAL	083735-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Actavis Elizabeth	DEXTROAMPHETAMINE SULFATE	dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	203901-003	Nov 30, 2012	AB	RX	No	No
Azurity	DEXTROAMPHETAMINE SULFATE	dextroamphetamine sulfate	TABLET;ORAL	090533-007	Oct 25, 2011	AA	RX	No	No
Aurolife Pharma Llc	DEXTROAMPHETAMINE SULFATE	dextroamphetamine sulfate	TABLET;ORAL	202893-001	Jul 31, 2013	AA	RX	No	No

Expired US Patents for dextroamphetamine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-002	Mar 22, 2022
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-001	Mar 22, 2022
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-002	Mar 22, 2022
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-004	Mar 22, 2022

International Patents for dextroamphetamine

Country	Patent Number	Title	Estimated Expiration
Japan	2015535253	アンフェタミンの組成物及びアンフェタミンを経皮送達する方法
Argentina	098878	COMPOSICIONES Y MÉTODOS PARA ADMINISTRACIÓN TRANSDÉRMICA DE ANFETAMINA
Argentina	124577
Taiwan	I674900

Market Dynamics and Financial Trajectory for Dextroamphetamine

Last updated: February 14, 2026

What is the current market size and growth rate for dextroamphetamine?

Dextroamphetamine is a central nervous system stimulant used primarily for treating attention deficit hyperactivity disorder (ADHD) and narcolepsy. The global market for ADHD medication, which includes dextroamphetamine and its formulations, was valued at approximately $11.3 billion in 2022. The compound's market growth rate is driven by increasing diagnoses and a growing acceptance of pharmaceutical treatments.

Annual growth rates for ADHD medications are estimated between 6% and 8% from 2023 to 2028. The demand for dextroamphetamine specifically is steady, accounting for an estimated 35% of the total ADHD medication market. The growth rate is influenced by a rising prevalence of ADHD, approval of new formulations, and expanding treatment adoption in emerging markets.

How do patent expirations and generic competition impact revenue streams?

Patents protecting dextroamphetamine formulations generally extend until the early to mid-2020s, with some formulations patented as late as 2024 or 2025. Once patent protection expires, generic manufacturers can enter the market, resulting in significant price erosion and increased competition.

Generic versions typically sell at 50-70% lower prices than branded formulations. The entry of generics can reduce revenue for brand-name producers by 60-80% within the first year of generic launch. This dynamic impacts the financial trajectory of companies holding patents, such as Teva Pharmaceuticals, which led the market historically.

What are the key drivers and barriers influencing market growth?

Drivers:

• Rising ADHD diagnosis rates across children and adults.
• Increasing acceptance of pharmacological treatment options.
• Expanding healthcare infrastructure and insurance coverage.
• Development of long-acting formulations improving compliance.

Barriers:

• Regulatory restrictions around stimulant medications due to abuse potential.
• Stigmatization of mental health conditions.
• Competition from non-stimulant ADHD medications (e.g., atomoxetine).
• Stringent abuse deterrent measures impacting formulation options.

How has pricing and reimbursement landscape evolved?

Pricing for dextroamphetamine has stabilized in recent years due to competitive generic entries. Average wholesale prices (AWP) for branded dextroamphetamine can range from $200 to $300 per month, while generics are available for under $100. Insurance reimbursement policies have generally maintained favorable coverage, but formulary restrictions and prior authorization requirements persist.

States with high insurance penetration exhibit higher prescription rates. Payor support influences access, with private insurers often requiring step therapy, delaying increased revenue potential for innovative formulations.

What are forecasted financial trends over the next five years?

Projections indicate the ADHD medication market will reach $16.8 billion by 2028, growing at 6% annually. Dextroamphetamine's share is expected to decline from 35% of the ADHD market to approximately 20-25% after patent expirations and proliferation of generic options.

Companies with diversified portfolios and early-generation patent protections will likely maintain higher revenues. For example, if current sales are approximately $4 billion annually, sales could decline to around $2-2.5 billion after five years unless new formulations or indications emerge.

How could regulatory and legal factors influence future market potential?

Regulatory agencies, such as the FDA, impose restrictions on stimulant prescriptions to prevent misuse. Changes in policy, including tighter controls or reclassification, could limit access or increase oversight costs. Conversely, approval of non-stimulant alternatives or reformulations with abuse-deterrent features may shift market dynamics.

Legal challenges related to abuse and diversion have led to increased enforcement and potential class actions. Companies that develop tamper-resistant formulations or alternative delivery systems may sustain market share longer-term.

---

Key Takeaways

• The dextroamphetamine market is part of the broader ADHD drug segment, valued at over $11 billion in 2022.
• Patent expirations starting early 2020s introduce significant generic competition, reducing revenues.
• Market growth is driven by rising ADHD prevalence, but faces barriers from regulation and competition from non-stimulant drugs.
• Pricing has dropped for generics, with reimbursement policies affecting access.
• Forecasts project market expansion overall, but dextroamphetamine’s direct revenue share could decline considerably without innovation.

---

FAQs

1. When do major patents for dextroamphetamine expire?
Most patents are set to expire between 2024 and 2025, opening the market to generic competition.

2. How much revenue to brand-name dextroamphetamine products generate annually?
Estimates suggest around $4 billion globally in 2022, but likely to decline after patent expiry.

3. What alternatives compete with dextroamphetamine for ADHD treatment?
Non-stimulant drugs such as atomoxetine, and other stimulants like methylphenidate.

4. How do regulatory changes impact the market?
Stringent controls and abuse deterrent requirements may limit prescriptions or raise formulation costs.

5. What are growth prospects for dextroamphetamine formulations?
Limited without innovation; market share expected to shrink as generics dominate, unless new indications or reformulations are introduced.

---

References

[1] IQVIA, "The Pharmaceutical Market Analysis," 2022.
[2] Grand View Research, "ADHD Drugs Market Size, Share & Trends," 2023.
[3] FDA, "Guidance Documentation on Stimulant Medications," 2022.
[4] EvaluatePharma, "2023 WorldPreview: Outlook to 2028," 2023.